Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2007

Signoroni Stefano, Frattini Milo, Negri Tiziana, Pastore Elisa, Tamborini Elena, Casieri Paola, Orsenigo Marta, Da Riva Luca, Radice Paolo, Sala Paola, Gronchi Alessandro, Bertario Lucio, Pierotti Marco A, Pilotti Silvana

Abstract excerpt

PURPOSE: To explore the molecular bases of potential new pharmacologic targets in aggressive fibromatosis (desmoid tumor). EXPERIMENTAL DESIGN: Tumor specimens from 14 patients surgically treated for aggressive fibromatosis (6 familial adenomatous polyposis and 8 sporadic cases), analyzed for adenomatous polyposis coli (APC) and CTNNB1 (beta-catenin) mutations, were further investigated for beta-catenin,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Cyclooxygenase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase 2 Inhibitors

Share to Desmoid Tumors

Share to Genes, APC

Share to Immunohistochemistry

Share to Receptors, Platelet-Derived Growth Factor

Share to RNA, Messenger

Source

Identifiers

PMID: 17785554
DOI: 10.1158/1078-0432.CCR-07-0336

Genes

PDGFRB
PDGFRA
CTNNB1
APC
KIT
PDGFA
PDGFB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.PMID 17785554Read ↗

Immunohistochemical evaluation of potential molecular targets of desmoid-type fibromatosis.Semantic proximity Read ↗

The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors).Semantic proximity Read ↗

Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature ReviewSemantic proximity Read ↗

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor.Semantic proximity Read ↗

[Agressive fibromatosis: genetic and biological correlations].Semantic proximity Read ↗

Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.Semantic proximity Read ↗

The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic targetSemantic proximity Read ↗

Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors).Semantic proximity Read ↗

A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders.Semantic proximity Read ↗

Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.Semantic proximity Read ↗

Aggressive fibromatosis.Semantic proximity Read ↗

Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.